As data from human and experimental TLE indicate that GJ inhibition is mediated by phosphorylation-mediated closure of Cx43 channels [12,76], compounds that disrupt aberrant Cx phosphorylation may have therapeutic potential in the treatment of epilepsy. This evidence concerns the gene GJA1 and epilepsy.